CAMP

CAMP4 THERAPEUTICS CORPORATION Healthcare - Biotechnology Investor Relations →

YES
4.4% BELOW
↓ Approaching Was 4.8% last week
-15% -10% -5% 0% 5% 10% 15%+
Buy Threshold $4.23
14-Week RSI 50
Rel. Volume (14w) This week's trading vs. the 14-week average 0.5x
Buyers vs. Sellers (14w) Are up-weeks or down-weeks getting more volume? 2.64 — Buyers winning

CAMP4 THERAPEUTICS CORPORATION (CAMP) closed at $4.05 as of 2026-05-01, trading 4.4% below its 200-week moving average of $4.23. This places CAMP in the below line zone. The stock is currently moving closer to the line, down from 4.8% last week. The 14-week RSI sits at 50, indicating neutral momentum.

Over the past 14 weeks, up-weeks have carried more volume than down-weeks (2.64 buyers-vs-sellers ratio). When trading picks up, it's more often on days the price is rising — buyers are showing more interest than sellers.

Over the past 33 weeks of data, CAMP has crossed below its 200-week moving average 4 times. On average, these episodes lasted 4 weeks.

With a market cap of $210 million, CAMP is a small-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at -145.1%. The stock trades at 4.4x book value.

Share count has increased 166.1% over three years, indicating dilution.

In the past 12 months, corporate insiders have made 7 open-market purchases totaling $15,563,424. Multiple insiders purchased within a 30-day window — a cluster buy pattern that historically signals management confidence in the company's prospects. Notably, these purchases occurred while CAMP is trading below its 200-week moving average — insiders are buying when the market is most pessimistic.

Free cash flow has been declining. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.

Business Health

Annual financials — how the underlying business has performed over the past several years.

Cash Flow Free cash flow & net income ($M)

Revenue Annual revenue ($M) — business growth proxy

Total Debt Balance sheet debt ($M)

ROIC Return on invested capital (%)

FCF Yield Free cash flow / market cap (%) — Yartseva signal

Gross Margin Pricing power & competitive moat (%)

Shares Outstanding Buybacks vs dilution (millions)

Advertisement

Insider Buying Activity

3 conviction buys in the past 12 months (purchases over $500K with meaningful position increases). 🔥 Cluster Buy Detected

DateInsiderTitleValueSharesPosition +%
2025-09-11NASHAT AMIR H.Director and Beneficial Owner of more than 10% of a Class of Security$3,647,0571,307,189+49.8%
2025-09-11POLARIS MANAGEMENT CO. VII, L.L.CBeneficial Owner of more than 10% of a Class of Security$3,647,0571,307,189+49.8%
2025-09-115AM PARTNERS VI, LLCBeneficial Owner of more than 10% of a Class of Security$8,176,4692,941,176+100.5%

Historical Touches

CAMP has crossed below its 200-week MA 4 times

Crossed BelowRecoveredWeeksMax Depth1-Year ReturnReturn Since Touch
Sep 2025Oct 2025644.9%N/A+77.6%
Nov 2025Dec 2025328.3%N/A+39.7%
Jan 2026Feb 2026411.9%N/A+1.0%
Apr 2026Ongoing1+4.4%OngoingN/A

Frequently Asked Questions

Is CAMP below its 200-week moving average?

Yes. As of 2026-05-01, CAMP4 THERAPEUTICS CORPORATION (CAMP) is trading 4.4% below its 200-week moving average of $4.23. The current price is $4.05.

What is CAMP's 200-week moving average price?

CAMP4 THERAPEUTICS CORPORATION's 200-week moving average is $4.23 as of 2026-05-01. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.

What happens when CAMP drops below its 200-week moving average?

CAMP has crossed below its 200-week moving average 4 times in our data. These episodes lasted 4 weeks on average.

Is CAMP a good value right now?

Here's what our data says about CAMP as of 2026-05-01: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 50. Free cash flow is currently negative. Return on equity is -145.1%. Price-to-book is 4.4x. This is not a buy or sell recommendation — always do your own research.

Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.

Data as of week of 2026-05-01